Respiratory viruses. Current status and future prospects.
The application of tissue culture technology has revealed several new groups of viruses, comprising scores of different serotypes, as important causes of upper and lower respiratory tract disease in man. Other agents as yet unrecognized undoubtedly exist. Present epidemiologic data, although still incomplete, point up the unique importance of certain of these viruses in respiratory diseases. The particular type and severity of respiratory syndrome produced by a virus is determined by the immune status of the host, by the presence of complicating disease and by characteristics intrinsic in the infecting agent itself. Respiratory virus control might be particularly beneficial in certain groups, particularly persons with allergic sensitivity and chronic pulmonary disease.For control of viral respiratory disease, active immunization would provide significant protection but highly polyvalent vaccines might be necessary. Adjuvants could be helpful in this regard. Certain vaccines formerly in use were produced from strains of viruses which have recently been shown to be oncogenic in animals. In addition, hybridization of viruses can occur, resulting in the incorporation of the oncogenic potential of one agent into the genetic constitution of another. The significance of these biologic phenomena to vaccination programs has yet to be defined.Passive immunization would provide short-lived protection and would find application only in uniquely susceptible populations or at times of augmented risk. Active immunization of pregnant women, however, could provide increased breadth and duration to the transplacental passive immunity in the newborn.Interferon-inducing agents could potentially provide broad spectrum antiviral protection, but the extent and duration of their effectiveness are unknowns. Certain chemical agents have been shown to have prophylactic and therapeutic effects against a limited number of clinically severe viral diseases. Finally, limited data suggest that climatic control in places of public gathering might be worth evaluating as a means of controlling the spread of viral respiratory infections.
D006801:Humans; D012141:Respiratory Tract Infections; D014777:Virus Diseases; D014780:Viruses / Q000145:classification
N Engl J Med. 1958 Jan 30;258(5):207-13
13504446
Science. 1964 May 15;144(3620):862-3
14151624
Proc Soc Exp Biol Med. 1959 Apr;100(4):843-5
13645739
Am Rev Respir Dis. 1964 Nov;90:683-706
14211456
JAMA. 1962 Jan 13;179:120-5
13870133
Proc Soc Exp Biol Med. 1962 Feb;109:251-2
14454445
Ann N Y Acad Sci. 1956 Aug 10;66(1):226-30
13395262
Pediatrics. 1963 Oct;32:599-609
14069102
Virology. 1962 May;17:65-75
13889129
Proc Soc Exp Biol Med. 1953 Dec;84(3):570-3
13134217
Am J Dis Child. 1962 Oct;104:330-4
13959448
Proc Natl Acad Sci U S A. 1964 Dec;52:1333-40
14243505
Proc Soc Exp Biol Med. 1961 Oct;108:205-9
13897896
J Natl Cancer Inst. 1962 Oct;29:765-87
13972899
Proc Soc Exp Biol Med. 1961 Oct;108:56-9
14476249
Lancet. 1960 May 21;1(7134):1110-1
13797621
Arch Ophthalmol. 1963 May;69:626-9
14031370
JAMA. 1962 Feb 24;179:594-7
14472203
JAMA. 1963 Aug 31;185:713-8
13959363
Science. 1962 Sep 14;137(3533):835-41
13922417
Proc Soc Exp Biol Med. 1960 Nov;105:420-7
13774265
JAMA. 1962 May 12;180:445-53
13907408
Ann N Y Acad Sci. 1957 Apr 19;67(8):262-72
13411964
Proc Natl Acad Sci U S A. 1964 Dec;52:1316-8
14243502
Lancet. 1960 Jan 30;1(7118):235-7
13840112
N Engl J Med. 1959 Jul 9;261(2):64-8
13666979
Bull World Health Organ. 1960;22:431-3
13838590
Virology. 1963 Sep;21:48-55
14062910
N Engl J Med. 1964 Jan 16;270:123-7
14067009
N Engl J Med. 1962 Jul 12;267:68-72
14452065
Nature. 1961 Jan 21;189:247-8
13767007
Proc Soc Exp Biol Med. 1956 Jul;92(3):544-9
13359460
Lancet. 1963 Jul 20;2(7299):113-6
13956740